Open an account

IN8bio

INAB · NASDAQ

$1.14+$0.05 (+4.59%)TodayMarket closed ·
Prev close $1.09

INAB analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $7.14 (+526.3% upside)

Low
$5.05
Now
$1.14
High
$10.50

Upgrades and downgrades

The latest rating actions, newest first

INAB analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Mar 13, 2026MaintainsBuy

The case for and against

Updated Jul 31, 2025

Bull case

IN8bio Inc demonstrates a positive outlook due to the promising efficacy of its lead product candidate, INB-100, which has shown a 100% overall survival rate at one year in high-risk acute myeloid leukemia (AML) patients undergoing haploidentical stem cell transplantation, significantly surpassing the historical 70% survival rate. The company’s ongoing multi-center expansion cohort study is expected to further validate these results, as it enrolls more patients and aims for completion in 2025. Additionally, the favorable safety profile of INB-100, with no reported treatment-related deaths or severe side effects, bolsters investor confidence in the product's potential for successful commercialization.

Bear case

IN8bio Inc's outlook is negatively impacted by a reduced price target of $6.00, down from $8.00, indicating diminished investor confidence in the company's financial prospects. Despite some potential shown by INB-619 in preclinical studies, the overall commercial viability of its gamma-delta T cell product candidates faces significant uncertainty, particularly given the competitive landscape in oncology. Furthermore, the company's reliance on early-stage product candidates, such as INB-400 and INB-100, contributes to heightened financial risks associated with clinical trial outcomes and long-term market acceptance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.